Health Care • Medical/Dental Instruments
$1.97 ▼ -0.11
(-5.29%)
MKT CAP: $15.8M • VOL: 5.4K
52W L $2 52W H $28
ROARABLE / RQD
E • 31/100
PIOTROSKI
1 / 9
PAVM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $71.0K | $3.0M | $2.5M |
| YoY Revenue Growth % | -97.6% | +22.1% | — |
| Gross Profit | -$147.0K | -$1.8M | — |
| Gross Margin % | -50.0% | -50.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$21.8M | -$44.5M | -$68.8M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$3.8M | $32.0M | -$66.3M |
| EBITDA (Normalized) | -$21.8M | -$44.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.2M | -$33.6M | -$52.0M |
| Capital Expenditures (CapEx) | $31.0K | $55.0K | — |
| Free Cash Flow (FCF) | -$5.2M | -$33.6M | -$52.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.5M | $1.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $34.0M | -$2.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PAVM.